Since release of the guidance and excluding the ONCO/Reveal Diagnostic Lung and Colon Cancer Assay, an additional two EGFR CDx devices were identified, bringing the total EGFR CDx devices appropriate for the same therapeutic class labeling to five (Table 2). This evidence concerns the gene EGFR and colonic neoplasm.